溶瘤病毒
溶癌病毒
癌症研究
生物
溶瘤腺病毒
人口
遗传增强
抄写(语言学)
基因
转录因子
融合基因
基因传递
腺病毒科
体内
癌症
转导(生物物理学)
癌细胞
基因表达
癌基因
肺癌
病毒载体
肿瘤细胞
病毒复制
基因表达调控
医学
细胞培养
信号转导
细胞
作者
Qi Liu,Qiqi Xiong,Guanglei Xie,Qidi Chen,Shujie Yang,Yuhang Wu,Liuqi Zhao,Ting Gao,Xinyuan Qiu,Jian Jiang,Xi Wang,Jiawei Shao,Mingqi Xie,Songmin Ying
标识
DOI:10.1016/j.xcrm.2026.102936
摘要
Gene therapies that selectively eliminate tumor cells within a heterogenous population remain an elusive goal in oncology, largely due to the difficulty to achieve cancer specificity by strict definition. Here, we engineer a therapeutic gene circuit capable of identifying cells that harbor oncogenic gain-of-function aberrations in E26 transformation-specific (ETS) transcription factors. Using a machine learning-guided random forest framework, we develop a cancer-selective promoter P ETS∗ that only activates during ETS overexpression and/or gene fusion events, while remaining inactive under physiological RAF-MEK-ERK signaling or in rapidly proliferating healthy tissues. When delivered using adenoviral vectors, P ETS∗ enables tumor-restricted viral replication in vivo as well as long-lasting tumor suppression and complete survival of treated mice. Specifically, intratracheal delivery of P ETS∗ -driven adenoviruses achieves sustained control of metastatic lung tumors for over 140 days. This work overcomes key barriers of synthetic biology and oncolytic virotherapy and could open up important avenues for future cancer treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI